- Previous Close
5,305.70 - Open
5,305.05 - Bid --
- Ask --
- Day's Range
5,281.20 - 5,337.00 - 52 Week Range
3,950.00 - 6,451.15 - Volume
4,521 - Avg. Volume
41,436 - Market Cap (intraday)
243.069B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
39.37 - EPS (TTM)
134.96 - Earnings Date Feb 7, 2025 - Feb 11, 2025
- Forward Dividend & Yield 35.00 (0.66%)
- Ex-Dividend Date Aug 21, 2024
- 1y Target Est
5,935.00
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
www.pfizerltd.co.in1,721
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: PFIZER.NS
View MorePerformance Overview: PFIZER.NS
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PFIZER.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PFIZER.NS
View MoreValuation Measures
Market Cap
243.07B
Enterprise Value
220.78B
Trailing P/E
39.34
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.86
Price/Book (mrq)
6.48
Enterprise Value/Revenue
9.87
Enterprise Value/EBITDA
24.32
Financial Highlights
Profitability and Income Statement
Profit Margin
27.61%
Return on Assets (ttm)
9.63%
Return on Equity (ttm)
17.59%
Revenue (ttm)
22.38B
Net Income Avi to Common (ttm)
6.18B
Diluted EPS (ttm)
134.96
Balance Sheet and Cash Flow
Total Cash (mrq)
22.81B
Total Debt/Equity (mrq)
1.99%
Levered Free Cash Flow (ttm)
3.39B